RxDoctor Payments Data

Beth Leventhal, MD

Nephrology · Pembroke Pines, FLNPI 1265468797

Payments from drug & device makers

$4,288in general payments, 2019–2025

Across 100 payments — averaging $42.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$2K
  • AstraZeneca$292
  • Otsuka America Pharmaceutical, Inc.$259
  • Amgen$239
  • Travere Therapeutics, Inc.$226
  • Bayer$222
  • plus $892 from 13 others

What the payments were for

  • Consulting fees$2,00047%
  • Food & beverage$2,28853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,288 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$186,492
Medicare patients
269
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol141$159,322
VelphoroSucroferric Oxyhydroxide25$43,024
InvokanaCanagliflozin31$38,252
JardianceEmpagliflozin26$34,959
OzempicSemaglutide23$29,562
TradjentaLinagliptin26$28,901
KerendiaFinerenone14$20,537
VeltassaPatiromer Calcium Sorbitex12$14,758
Sevelamer Carbonate57$11,713
SpsSodium Polystyrene Sulfon/Sorb39$8,673
Cinacalcet Hcl55$4,733
Nifedipine ErNifedipine85$3,081
Calcium Acetate40$2,334
Potassium Citrate ErPotassium Citrate13$1,244
Potassium Chloride27$1,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$292$159,322141 claims
Boehringer IngelheimJardiance, Tradjenta$204$63,86052 claims
Fresenius USA Marketing, Inc.Velphoro$27$43,02425 claims
Novo NordiskOzempic$44$29,56223 claims
BayerKerendia$222$20,53714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →